Wenming Chen

Summary

Country: China

Publications

  1. Zhou H, Li J, Jian Y, Chen T, Deng H, Zhang J, et al. Effects and mechanism of arsenic trioxide in combination with rmhTRAIL in multiple myeloma. Exp Hematol. 2016;44:125-131.e11 pubmed publisher
    ..Our study provides evidence of a potential new combination treatment strategy for MM. ..
  2. Leng Y, Qiu L, Hou J, Zhao Y, Zhang X, Yang S, et al. Phase II open-label study of recombinant circularly permuted TRAIL as a single-agent treatment for relapsed or refractory multiple myeloma. Chin J Cancer. 2016;35:86 pubmed publisher
    ..CPT as a single agent can elicit a response in patients with RRMM and is well tolerated. Further clinical investigation is warranted. Trial Registration ChiCTR-ONC-12002065 http://www.chictr.org/cn. ..
  3. Zhou H, Jian Y, Leng Y, Liu N, Tian Y, Wang G, et al. Human MutT homologue 1 mRNA overexpression correlates to poor response of multiple myeloma. Int J Hematol. 2017;105:318-325 pubmed publisher
    ..04). In conclusion, higher MTH1 may be associated with later disease stage and advanced disease progression. MTH1 mRNA overexpression is also correlated poor efficacy of bortezomib in newly diagnosed MM patients. ..
  4. Leng Y, Hou J, Jin J, Zhang M, Ke X, Jiang B, et al. Circularly permuted TRAIL plus thalidomide and dexamethasone versus thalidomide and dexamethasone for relapsed/refractory multiple myeloma: a phase 2 study. Cancer Chemother Pharmacol. 2017;79:1141-1149 pubmed publisher
    ..7% of the patients. No treatment-related deaths were reported. CPT plus TD could serve as a new therapeutic strategy for patients with RRMM. A randomized, double-blind, placebo-controlled confirmatory study is currently under way. ..